We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+3.61%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$266M
AUM Growth
-$11.2M
Cap. Flow
-$5.98M
Cap. Flow %
-2.25%
Top 10 Hldgs %
90.94%
Holding
15
New
–
Increased
6
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$7.98M
2
BPMC
Blueprint Medicines
BPMC
+$2.76M
3
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$705K
4
PVLA
Palvella Therapeutics
PVLA
+$519K
5
SLN
Silence Therapeutics
SLN
+$275K

Top Sells

Rank Stock Value
1
SPRO icon
Spero Therapeutics
SPRO
+$6.81M
2
QURE icon
uniQure
QURE
+$4.67M
3
ARWR icon
Arrowhead Research
ARWR
+$3.81M
4
RGNX icon
Regenxbio
RGNX
+$1.58M
5
MRUS
Merus
MRUS
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 84.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.4B
$44.8M 16.81%
1,103,515
-115,000
-9% -$3.81M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$41.5M 15.59%
500,000
– –
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$25.5M 9.57%
581,768
+57,500
+11% +$2.76M
ARVN icon
4
Arvinas
ARVN
$572M
$23.1M 8.66%
673,941
+2,196
+0.3% +$92.4K
MRUS
5
DELISTED
Merus
MRUS
$22.2M 8.32%
1,432,109
-75,000
-5% -$1.32M
RGNX icon
6
Regenxbio
RGNX
$708M
$20.4M 7.65%
897,684
-70,000
-7% -$1.58M
SLN
7
Silence Therapeutics
SLN
$564M
$19.6M 7.36%
1,284,133
+21,008
+2% +$275K
KYMR icon
8
Kymera Therapeutics
KYMR
$8.94B
$15.7M 5.9%
629,411
+299,165
+91% +$7.98M
AMYT
9
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$15.3M 5.76%
2,098,993
+100,000
+5% +$705K
QURE icon
10
uniQure
QURE
$3.22B
$14.2M 5.32%
624,854
-216,617
-26% -$4.67M
GMAB icon
11
Genmab
GMAB
$19.5B
$10.3M 3.87%
242,848
-2,000
-0.8% -$82.4K
ARGX icon
12
argenx
ARGX
$54.1B
$9.09M 3.42%
24,000
– –
PVLA
13
Palvella Therapeutics
PVLA
$2.27B
$4.73M 1.78%
56,911
+6,457
+13% +$519K
FDMT icon
14
4D Molecular Therapeutics
FDMT
$562M
– –
-3,573
Closed -$29K
SPRO icon
15
Spero Therapeutics
SPRO
$73M
– –
-3,403,210
Closed -$6.81M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Aquilo Capital Management held 15 positions worth $266M, down 4% from $277M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Aquilo Capital Management's Q4 2022 filing shows 6 increased, 5 reduced and 2 closed positions. The largest sale was Spero Therapeutics, an estimated $6.81M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 86% a quarter earlier.

  • Aquilo Capital Management added most to Kymera Therapeutics in Q4 2022, an estimated $7.98M increase.
  • Aquilo Capital Management's biggest Q4 2022 reduction was uniQure, cutting an estimated $4.67M.
  • Aquilo Capital Management fully exited Spero Therapeutics in Q4 2022, selling an estimated $6.81M.
  • Aquilo Capital Management's ten largest holdings make up 91% of its $266M portfolio in Q4 2022.
  • Aquilo Capital Management opened 0 new positions and closed 2 in Q4 2022.
  • Aquilo Capital Management's portfolio value fell 4% quarter-over-quarter to $266M.

Based on Aquilo Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.